Marcelo do Rego Maciel Souto Maior

Dr. Marcelo do Rego Maciel Souto Maior

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MMMarcelo do Rego Maciel Souto Maior
Marcelo do Rego Maciel Souto Maior
NRNATHALIA RIBEIRO
NATHALIA RIBEIRO
HSHannah Silva
Hannah Silva
ELEdmundo Pessoa Lopes
Edmundo Pessoa Lopes
ECEmilia Chagas Costa
Emilia Chagas Costa
Metabolic dysfunction-associated steatotic liver disease (MASLD)—previously known as non-alcoholic fatty liver disease (NAFLD)—is currently the most common chronic liver disease globally. Observational studies have reported that MASLD is independently associated with extrahepatic disorders, such as chronic kidney disease (CKD). Severe forms of MASLD (i.e., steatohepatitis and liver fibrosis) are even more strongly associated with the risk of incident kidney dysfunction. Hypothetically, MASLD could directly promote CKD through liver-derived endocrine and metabolic mediators, hemodynamic alterations, immune-mediated mechanisms, and oxidative or cellular stress. However, proving that MASLD directly causes CKD is difficult due to the multiple shared cardiometabolic and systemic risk factors, such as obesity, hypertension, and type 2 diabetes mellitus, which serve as confounding variables. Moreover, studies on the association between MASLD and CKD have differed in their designs, sampling methods, disease definitions, and inclusion criteria, precluding more robust evidence supporting a causal relationship. Furthermore, few studies have explored specific issues, such as the new nomenclature for steatotic liver disease, the relationship between these diseases in pediatric populations, the impact of MASLD plus alcohol intake (MetALD) on CKD, and therapeutic options targeting MASLD and CKD simultaneously. Answers to these issues are essential, as the appropriate management of patients with MASLD may prevent or ameliorate kidney dysfunction. The aims of the present study are to describe shared risk factors between MASLD and CKD, the possible direct pathogenic effect of MASLD on kidney structure and function, and gaps in the current literature, to indicate future research directions.

17 December 2025 in Jornal de Pediatria
Verified
Journal Article
Open access
CAChristine Audet de Almeida
Christine Audet de Almeida
ESEduardo Sampaio Siqueira
Eduardo Sampaio Siqueira
MMMarcelo do Rego Maciel Souto Maior
Marcelo do Rego Maciel Souto Maior
KBKátia Galeão Brandt
Kátia Galeão Brandt
Describe the occurrence of warning signs of gastroesophageal reflux disease (GERD) and esophagitis in children with eating behavior (EB) alterations associated with autism spectrum disorder (ASD). Descriptive study of 115 children aged 3 to 12 years, followed at a tertiary hospital and previously diagnosed with ASD. The BRCA-TEA instrument was applied to identify children with EB alterations, and the 17-ATN-GISSI instrument was applied to identify those with warning signs of GERD. The selected children were invited for a medical consultation to identify those with suspected esophagitis and an indication for upper gastrointestinal (GI) endoscopy with biopsies. Sixty-nine children (60 %) were classified with alterations in the EB and, among these, 62 (89.8 %) presented warning signs of GERD. Eighteen children had suspected esophagitis and an indication for upper GI endoscopy. Among the 8 children who underwent the exam, 1 child had grade A erosive esophagitis, 1 child had grade B erosive esophagitis, and 1 child had eosinophilic esophagitis. A high frequency of EB alterations was found in children with ASD. The high frequency of GERD warning signs may be related to EB alterations in this group. Cases of esophagitis highlight the possibility of an organic disease. In these cases, performing upper GI endoscopy with biopsies is essential for diagnosis.

7 February 2026 in Revista Brasileira de Cirurgia Plástica (RBCP) – Brazilian Journal of Plastic Surgery
Verified
Journal Article
Open access
BJBartolomeu Antonio Nascimento Junior
Bartolomeu Antonio Nascimento Junior
JSJairo Zacchê de Sá
Jairo Zacchê de Sá
LGLuiz José Muaccad Gama
Luiz José Muaccad Gama
PPPedro Celso de Castro Pita
Pedro Celso de Castro Pita
BMBernardo Schwartz e Mello
Bernardo Schwartz e Mello
MAMarcelo Rodrigues da Cunha Araújo
Marcelo Rodrigues da Cunha Araújo
Resumo: A técnica Freelift para rejuvenescimento cervicofacial é uma abordagem biplanar, com ampla liberação sub-sistema musculoaponeurótico superficial (SMAS)-platisma; e, portanto, requer conhecimento avançado de anatomia facial e destreza cirúrgica. Descrever a anatomia topográfica das zonas faciais no-touch na cirurgia de Freelift. Estudo prospectivo da anatomia facial por meio de dissecções padronizadas de cadáveres. Os retalhos dermogordurosos e de SMAS-platisma foram inicialmente confeccionados mimetizando o Freelift. Em seguida, foram ampliados para exposição de toda a hemiface. As características topográficas das zonas faciais no-touch foram analisadas. Os pontos de referência para as zonas faciais no-touch foram descritos. Análises histológicas de SMAS foram realizadas. Setenta e quatro famílias foram abordadas, 40 consentiram (54% de taxa de consentimento) em tomar parte do estudo. As hemifaces de 37 cadáveres foram dissecadas. A zona zigomática no-touch inicia-se a 4,5 ± 0,3 cm da incisura supratragal e contém o músculo zigomático maior, o ramo zigomático do nervo facial e o ducto da glândula parótida. As alças superior e inferior do ramo bucal, a gordura bucal e o músculo risório situam-se dentro das zonas bucais no-touch. A zona cervical no-touch mantém os ramos cervicais superiores superficiais a 3,6 ± 0,3 cm do ângulo goníaco. O SMAS móvel é inexistente na histologia. Este estudo com espécimes frescos permitiu a descrição das zonas faciais no-touch na técnica Freelift. Essas zonas contêm estruturas importantes e devem permanecer intactas durante a criação do segmento composto do retalho Freelift. Por fim, a padronização cirúrgica é crucial para realizar a abordagem Freelift com segurança.

28 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMarcelo do Rego Maciel Souto Maior
Marcelo do Rego Maciel Souto Maior
NRNATHALIA RIBEIRO
NATHALIA RIBEIRO
HSHannah Silva
Hannah Silva
ELEdmundo Pessoa Lopes
Edmundo Pessoa Lopes
ECEmilia Chagas Costa
Emilia Chagas Costa
Metabolic dysfunction-associated steatotic liver disease (MASLD) - previously known as nonalcoholic fatty liver disease (NAFLD) - is currently the most common chronic liver disease globally. Observational studies have reported that MASLD is independently associated with extrahepatic disorders, such as chronic kidney disease (CKD). Severe forms of MASLD (i.e. steatohepatitis and liver fibrosis) are even more strongly associated with the risk of incident kidney dysfunction. Hypothetically, MASLD could directly promote CKD through liver-derived endocrine and metabolic mediators, hemodynamic alterations, immune-mediated mechanisms and oxidative or cellular stress. However, proving that MASLD directly causes CKD is difficult due to the multiple shared cardiometabolic and systemic risk factors, such as obesity, hypertension and type 2 diabetes mellitus, which serve as confounding variables. Moreover, studies on the association between MASLD and CKD have differed in their designs, sampling methods, disease definitions and inclusion criteria, precluding more robust evidence supporting a causal relationship. Furthermore, few studies have explored specific issues, such as the new nomenclature for Steatotic Liver Disease, the relationship between these diseases in pediatric populations, the impact of MASLD plus alcohol intake (MetALD) on CKD, and therapeutic options targeting MASLD and CKD simultaneously. Answers to these issues are essential, as the appropriate management of patients with MASLD may prevent or ameliorate kidney dysfunction. The aims of the present study are to describe shared risk factors between MASLD and CKD, the possible direct pathogenic effect of MASLD on kidney structure and function, and gaps in the current literature, to indicate future research directions.